Patents by Inventor Lere Bao
Lere Bao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170184600Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.Type: ApplicationFiled: August 9, 2016Publication date: June 29, 2017Inventors: BRUCE R. ZETTER, Lere Bao, Jacqueline Banyard
-
Publication number: 20120115134Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.Type: ApplicationFiled: July 12, 2011Publication date: May 10, 2012Applicant: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
-
Patent number: 7993863Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.Type: GrantFiled: March 18, 2003Date of Patent: August 9, 2011Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
-
Patent number: 7592145Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.Type: GrantFiled: June 5, 2006Date of Patent: September 22, 2009Assignee: Pintex Pharmaceuticals, Inc.Inventors: Lere Bao, Da Gong Wang
-
Publication number: 20060216764Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.Type: ApplicationFiled: June 5, 2006Publication date: September 28, 2006Inventors: Lere Bao, Da Wang
-
Publication number: 20060105343Abstract: We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.Type: ApplicationFiled: January 7, 2004Publication date: May 18, 2006Applicant: Children's Medical Center CorporationInventors: Bruce Zetter, Lloyd Hutchinson, Lere Bao
-
Publication number: 20060078882Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.Type: ApplicationFiled: March 18, 2003Publication date: April 13, 2006Inventors: Bruce Zetter, Lere Bao, Jacqueline Banyard
-
Publication number: 20040101910Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr; 15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr; 15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: ApplicationFiled: December 3, 2003Publication date: May 27, 2004Applicant: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Publication number: 20030073096Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin 1 and the amplification of Pin 1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.Type: ApplicationFiled: February 8, 2002Publication date: April 17, 2003Applicant: Pintex Pharmaceuticals, Inc.Inventors: Lere Bao, Da Gong Wang
-
Publication number: 20030068626Abstract: Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.Type: ApplicationFiled: February 8, 2002Publication date: April 10, 2003Applicant: Pintex Pharmaceuticals, Inc.Inventors: Da Gong Wang, Lere Bao
-
Publication number: 20020183496Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: ApplicationFiled: June 5, 2001Publication date: December 5, 2002Applicant: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 6489463Abstract: The present invention provides a thymosin &bgr;15 promoter. The promoter comprises the nucleotide sequence of SEQ ID NO:1 or a fragment thereof capable of expressing an operably linked DNA. A DNA sequence having nucleotides −400 to +1 of FIG. 1 is a preferred fragment. The invention also provides novel assays for identifying compounds useful in the treatment of malignancies involving modulation of thymosin &bgr;15 expression, e.g., breast, pancreas and prostate cancer. The invention further provides a method of human gene therapy for treating malignancies involving up-regulation of thymosin &bgr;15 expression.Type: GrantFiled: April 13, 2000Date of Patent: December 3, 2002Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 6300479Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: GrantFiled: August 6, 1999Date of Patent: October 9, 2001Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 6150117Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.Type: GrantFiled: August 18, 1998Date of Patent: November 21, 2000Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 6017717Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: GrantFiled: April 29, 1998Date of Patent: January 25, 2000Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 5858681Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.Type: GrantFiled: June 17, 1996Date of Patent: January 12, 1999Assignee: Children's Medical CenterInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 5831033Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: GrantFiled: September 17, 1997Date of Patent: November 3, 1998Assignee: Children's Medical Center of BostonInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 5721337Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: GrantFiled: February 14, 1997Date of Patent: February 24, 1998Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 5663071Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is directed to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).Type: GrantFiled: June 17, 1996Date of Patent: September 2, 1997Assignee: Children's Medical Center CorporationInventors: Bruce R. Zetter, Lere Bao